HBIO
NASDAQ · Life Sciences Tools & Services
Harvard Bioscience Inc
$9.52
+0.31 (+3.31%)
Financial Highlights (FY 2026)
Revenue
87.59M
Net Income
-57,381,053
Gross Margin
57.7%
Profit Margin
-65.5%
Rev Growth
-8.6%
D/E Ratio
2.61
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 57.7% | 57.7% | 46.9% | 46.9% |
| Operating Margin | -57.5% | -51.8% | 16.0% | 18.5% |
| Profit Margin | -65.5% | -62.2% | 12.2% | 11.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 87.59M | 95.82M | 6.41M | 5.41M |
| Gross Profit | 50.51M | 55.26M | 3.01M | 2.54M |
| Operating Income | -50,407,665 | -49,630,126 | 1.03M | 999.7K |
| Net Income | -57,381,053 | -56,495,949 | 780.8K | 611.3K |
| Gross Margin | 57.7% | 57.7% | 46.9% | 46.9% |
| Operating Margin | -57.5% | -51.8% | 16.0% | 18.5% |
| Profit Margin | -65.5% | -62.2% | 12.2% | 11.3% |
| Rev Growth | -8.6% | -8.6% | -3.7% | -0.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 13.58M | 13.58M | 1.63M | 1.53M |
| Total Equity | 5.20M | 5.20M | 13.87M | 13.47M |
| D/E Ratio | 2.61 | 2.61 | 0.12 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -46,336,024 | -48,155,806 | 1.44M | 1.03M |
| Free Cash Flow | — | — | 1.10M | 719.6K |